Stereotaxis, Inc.

AMEX:STXS

Medical - Instruments & Supplies

Healthcare
$0.95 +2.53%

+$0.05 today

Market cap
$94.80M
Beta
1.32
P/E (TTM)
-8.3
EPS (TTM)
-$0.22
52W Low $1.70High $3.59

Volume 0.90M

Average 0.39M

STXS Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Stereotaxis, Inc.AMEX: STXS

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$5.18M, compared with -$5.93M a year earlier. Trailing-twelve-month operating income was -$21.36M.

Context

  • Operating income amounted to 68.3% of revenue in FY2025, down 23.6 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 2 analysts of -$20.62M (+6.8%) for the fiscal year ending Dec 2026, a slowdown from the +10.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.18M+8.3% QoQ
Last fiscal yearDec 2025
-$22.11M+10.6% YoY
LTMMar 2026
-$21.36M+17.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.6%-28.9%-41.5 pp
1 year+10.6%+6.8%-3.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(22.11M) USD
Year-over-year change
+10.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How STXS compares with its peers on the latest reported figures

  • STXS's LTM Mar 2026 operating income of -$21.36M is the 4th highest of the 5 companies compared; the peer median is -$16.4M.
  • Its year-over-year change of +17.6% is the 2nd highest of 5, against a peer median of -4.6%.
  • Operating income amounts to 68.5% of revenue for STXS, versus a peer median of 41.0%.
STXS Competitors Peer median
Operating Income for STXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SSIISS Innovations International, Inc.LTM Mar 2026-$6.13M +68.6%—12.7%
MBOTMicrobot Medical Inc.LTM Mar 2026-$16.04M -30.8%—15278.1%
NPCENeuroPace, Inc.LTM Mar 2026-$16.76M +13.0%—16.8%
STXSStereotaxis, Inc.LTM Mar 2026-$21.36M +17.6%—68.5%
CLPTClearPoint Neuro, Inc.LTM Mar 2026-$26.48M -22.1%—65.2%
Peer median (excluding STXS) -$16.4M-4.6%—41.0%

Competitors are the stored peer set for STXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue35.02M28.15M26.77M26.92M32.38M
Cost of Revenue11.79M9.68M11.91M12.32M15.31M
Gross Profit23.23M18.47M14.86M14.59M17.07M
Gross Margin66.3%65.6%55.5%54.2%52.7%
Research & Development10.2M10.56M10.27M9.76M9.38M
Selling, General & Admin25.92M26.69M26.43M29.57M30.29M
Operating Expenses36.12M37.25M36.7M39.33M39.18M
Depreciation & Amortization106K429K595K969K1.56M
EBITDA(10.6M)(17.86M)(20.12M)(23.08M)(20.09M)
EBITDA Margin-30.3%-63.5%-75.1%-85.7%-62.0%
Operating Income(12.89M)(18.78M)(21.84M)(24.74M)(22.11M)
Operating Margin-36.8%-66.7%-81.6%-91.9%-68.3%
Interest Income0484K1.1M694K467K
Interest Expense10.07K0000
Other Income / Expenses2.17M484K1.13M694K469K
Income Before Tax(10.72M)(18.29M)(20.71M)(24.05M)(21.64M)
Pre-Tax Margin-30.6%-65.0%-77.4%-89.3%-66.8%
Income Tax Expense00000
Net Income(10.72M)(18.29M)(20.71M)(24.05M)(21.64M)
Net Margin-30.6%-65.0%-77.4%-89.3%-66.8%
EPS (Basic)(0.16)(0.26)(0.27)(0.30)(0.25)
EPS (Diluted)(0.16)(0.26)(0.27)(0.30)(0.25)
Weighted Avg Shares75.56M76.06M80.7M85.18M90.96M
Weighted Avg Shares (Diluted)75.56M76.06M80.7M85.18M90.96M

Stereotaxis, Inc.

AMEX:STXS

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.